Annual Report 2019–20

40 香港中文大學年報 CUHK Annual Report 2019–2020 CAR-T治療血癌新方法 大學將開展利用嵌合抗原受體T細胞 （CAR-T細胞）技術的細胞治療臨床研 究，首階段為血癌患者提供治療，並成立 香港首所符合「生產質量管理規範」的 CAR-T細胞實驗室。此新療法為病者提 供化療以及其他療法以外的選擇，研究 團隊並冀將CAR-T細胞治療應用到其他 癌症的治療。 CAR-T Cell Therapy for Haematological Malignancy The University would commence clinical trials of Chimeric antigen receptor-T (CAR-T) cell therapy, with the first phase serving patients with haematological malignancy, and establish Hong Kong’s first-ever CAR-T cell laboratory licensed with Good Manufacturing Practice. The therapy offers an alternative to chemotherapy as well as other treatment methods, and the team aims to extend the therapy to other types of cancer.